Cargando…
Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector
Wiskott-Aldrich syndrome (WAS) is a life-threatening immunodeficiency caused by mutations within the WAS gene. Viral gene therapy to restore WAS protein (WASp) expression in hematopoietic cells of patients with WAS has the potential to improve outcomes relative to the current standard of care, allog...
Autores principales: | Singh, Swati, Khan, Iram, Khim, Socheath, Seymour, Brenda, Sommer, Karen, Wielgosz, Matthew, Norgaard, Zachary, Kiem, Hans-Peter, Adair, Jennifer, Liggitt, Denny, Nienhuis, Arthur, Rawlings, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363182/ https://www.ncbi.nlm.nih.gov/pubmed/28344987 http://dx.doi.org/10.1016/j.omtm.2016.11.001 |
Ejemplares similares
-
Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy
por: Wielgosz, Matthew M, et al.
Publicado: (2015) -
Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis
por: Meyer-Bahlburg, Almut, et al.
Publicado: (2008) -
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector
por: Seymour, Brenda J., et al.
Publicado: (2021) -
Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome
por: Sereni, Lucia, et al.
Publicado: (2019) -
Síndrome de Wiskott - Aldrich /
por: Tello Gabriel, Adriana